Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

Molecular Oncology

Volumn 9, Issue 7, 2015, Pages 1447-1457

  Woan, K V ^a   Lienlaf, M ^a   Perez Villaroel, P ^a   Lee, C ^b   Cheng, F ^a   Knox, T ^a   Woods, D M ^a   Barrios, K ^a   Powers, J ^a   Sahakian, E ^a   Wang, H W ^a   Canales, J ^a   Marante, D ^a   Smalley, K S M ^a   Bergman, J ^c   Seto, E ^a   Kozikowski, A ^c   Pinilla Ibarz, J ^a   Sarnaik, A ^a   Celis, E ^d   Weber, J ^a   Sotomayor, E M ^a   Villagra, A ^a   more..

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d AUGUSTA UNIVERSITY   (United States)

Author keywords

HDAC6; Histone deacetylases; Melanoma; Nexturastat; Tubastatin A

Indexed keywords

ALPHA TUBULIN; CASPASE 3; CASPASE 8; CD4 ANTIGEN; CD8 ANTIGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN GP 100; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MELANOMA ANTIGEN; MOCETINOSTAT; NEXTURASTAT A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PANOBINOSTAT; PROTEIN BAX; TRICHOSTATIN A; TUBASTATIN A; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HDAC6 PROTEIN, MOUSE; HISTONE DEACETYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; METASTATIC MELANOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR IMMUNITY; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; EXPERIMENTAL MELANOMA; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 84938212386     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.04.002     Document Type: Article

References (43)

1. Archer S.Y., Meng S., Shei A., Hodin R.A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. U S A 1998, 95:6791-6796.
2. Atadja P., Gao L., Kwon P., Trogani N., Walker H., Hsu M., Yeleswarapu L., Chandramouli N., Perez L., Versace R., Wu A., Sambucetti L., Lassota P., Cohen D., Bair K., Wood A., Remiszewski S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004, 64:689-695.
3. Bergman J.A., Woan K., Perez-Villarroel P., Villagra A., Sotomayor E.M., Kozikowski A.P. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J. Med. Chem. 2012, 55:9891-9899.
4. Bhatia S., Tykodi S.S., Thompson J.A. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009, 23:488-496.
5. Bishton M., Kenealy M., Johnstone R., Rasheed W., Prince H.M. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Rev. Anticancer Ther. 2007, 7:1439-1449.
6. Buglio D., Khaskhely N.M., Voo K.S., Martinez-Valdez H., Liu Y.-J., Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011, 117:8.
7. Chang S., Young B.D., Li S., Qi X., Richardson J.A., Olson E.N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126:321-334.
8. Cheng F., Lienlaf M., Wang H.W., Perez-Villarroel P., Lee C., Woan K., Rock-Klotz J., Sahakian E., Woods D., Pinilla-Ibarz J., Kalin J., Tao J., Hancock W., Kozikowski A., Seto E., Villagra A., Sotomayor E.M. A novel role for histone deacetylase 6 in the regulation of the Tolerogenic STAT3/IL-10 pathway in APCs. J. Immunol. 2014, 193:2850-2862.
9. Chou S.D., Khan A.N., Magner W.J., Tomasi T.B. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int. Immunol. 2005, 17:1483-1494.
10. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
11. Daar A.S., Fabre J.W. The membrane antigens of human colorectal cancer cells: demonstration with monoclonal antibodies of heterogeneity within and between tumours and of anomalous expression of HLA-DR. Eur. J. Cancer Clin. Oncol. 1983, 19:209-220.
12. de Zoeten E.F., Wang L., Butler K., Beier U.H., Akimova T., Sai H., Bradner J.E., Mazitschek R., Kozikowski A.P., Matthias P., Hancock W.W. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol. Cell Biol. 2011, 31:2066-2078.
13. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., Chiao J.H., Reilly J.F., Ricker J.L., Richon V.M., Frankel S.R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
14. Fredriksson S., Dixon W., Ji H., Koong A.C., Mindrinos M., Davis R.W. Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat. Methods 2007, 4:327-329.
15. Glaser K.B., Li J., Staver M.J., Wei R.-Q., Albert D.H., Davidsen S.K. Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 2003, 310:529-536.
16. Hsieh C.L., Pang V.F., Chen D.S., Hwang L.H. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum. Gene Ther. 1997, 8:1843-1854.
17. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
18. Kamma H., Yazawa T., Ogata T., Horiguchi H., Iijima T. Expression of MHC class II antigens in human lung cancer cells. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1991, 60:407-412.
19. Khan A.N., Gregorie C.J., Tomasi T.B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer immunol. Immunother.: CII 2008, 57:647-654.
20. Khan A.N., Tomasi T.B. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol. Res. 2008, 40:164-178.
21. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl Res. 2011, 3:166-179.
22. Kim H.S., Zhang Y.H., Fang L.H., Yun Y.P., Lee H.K. Effects of tetrandrine and fangchinoline on human platelet aggregation and thromboxane B2 formation. J. Ethnopharmacol 1999, 66:241-246.
23. Kozikowski A.P., Tapadar S., Luchini D.N., Kim K.H., Billadeau D.D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem. 2008, 51:4370-4373.
24. Magner W.J., Kazim A.L., Stewart C., Romano M.A., Catalano G., Grande C., Keiser N., Santaniello F., Tomasi T.B. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 2000, 165:7017-7024.
25. Marks P.A., Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotech. 2007, 25:84-90.
26. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
27. Neuner A., Schindel M., Wildenberg U., Muley T., Lahm H., Fischer J.R. Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer 2001, 34(Suppl 2):S79-S82.
28. O'Sullivan Coyne G., Madan R.A., Gulley J.L. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J. Clin.oncol.: Off. J. Am. Soc. Clin. Oncol. 2014, 32:986-988.
29. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucl. Acids Res. 2001, 29:e45.
30. Piekarz R.L., Frye R., Turner M., Wright J.J., Allen S.L., Kirschbaum M.H., Zain J., Prince H.M., Leonard J.P., Geskin L.J., Reeder C., Joske D., Figg W.D., Gardner E.R., Steinberg S.M., Jaffe E.S., Stetler-Stevenson M., Lade S., Fojo A.T., Bates S.E. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2009, 27:5410-5417.
31. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive Strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267-296.
32. Rigel D.S. Epidemiology of melanoma. Semin. Cutan Med. Surg. 2010, 29:204-209.
33. Ruiter D.J., Mattijssen V., Broecker E.B., Ferrone S. MHC antigens in human melanomas. Semin. Cancer Biol. 1991, 2:35-45.
34. Serrador J.M., Cabrero J.R., Sancho D., Mittelbrunn M., Urzainqui A., Sanchez-Madrid F. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 2004, 20:417-428.
35. Serrano A., Tanzarella S., Lionello I., Mendez R., Traversari C., Ruiz-Cabello F., Garrido F. Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2prime-deoxycytidine treatment. Int. J. Cancer 2001, 94:243-251.
36. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA: A Cancer J. Clinicians 2013, 63:11-30.
37. Spiegel S., Milstien S., Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012, 31:537-551.
38. Thompson C.A. Belinostat approved for use in treating rare lymphoma. Am. J. Health-system Pharm. AJHP: Off. J. Am. Soc. Health-System Pharm. 2014, 71:1328.
39. Vo D.D., Prins R.M., Begley J.L., Donahue T.R., Morris L.F., Bruhn K.W., de la Rocha P., Yang M.Y., Mok S., Garban H.J., Craft N., Economou J.S., Marincola F.M., Wang E., Ribas A. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009, 69:8693-8699.
40. Watson M., Johnson C.J., Chen V.W., Thomas C.C., Weir H.K., Sherman R., Cockburn M., Jackson-Thompson J., Saraiya M. Melanoma surveillance in the United States: overview of methods. J. Am. Acad. Dermatol. 2011, 65:S6-S16.
41. Woan K.V., Sahakian E., Sotomayor E.M., Seto E., Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol. Cel. Biol. 2012, 90:55-65.
42. Woods D.M., Woan K., Cheng F., Wang H., Perez-Villarroel P., Lee C., Lienlaf M., Atadja P., Seto E., Weber J., Sotomayor E.M., Villagra A. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013, 5:341.
43. Wu C., Li A., Leng Y., Li Y., Kang J. Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. DNA Cel. Biol. 2012, 31:592-599.